Biote Announces Strategic Partnership with IMAC Holdings, Inc.
2022年9月7日 - 9:30PM
biote Corp. (Nasdaq: BTMD)(“Biote” or the “Company”), a high
growth, differentiated medical practice-building business within
the hormone optimization space, today announced that it has entered
into a partnership with IMAC Holdings, Inc. (Nasdaq: BACK)(“IMAC”)
a regenerative rehabilitation company focused on treating
musculoskeletal and neurodegenerative disease. Through this
partnership, IMAC will add certain Biote services to its network of
outpatient clinics that deliver orthopedic, regenerative, and
advanced, non-surgical medical procedures.
“As leaders in hormone optimization and
regenerative health and wellness, respectively, we believe Biote
and IMAC are well-positioned to make an exponential impact on the
lives of individuals who are hoping to live fuller, pain-free, and
healthy lives through all stages of aging. We are honored to embark
on this strategic partnership with a company whose mission aligns
so well with ours,” said Terry Weber, Biote Chief Executive
Officer. “We believe the future is incredibly bright for Biote,
IMAC, and all those who will benefit from our partnership.”
“We are excited to add Biote’s services to IMAC
clinics, which will be used to implement innovative weight loss and
hormone optimization therapy within our current patient
population,” said Jeff Ervin, IMAC Founder and Chief Executive
Officer. “Where IMAC has a focus on evidence-based regenerative
applications, Biote brings a similar focus to hormone optimization
which we see as a complementary service line to our existing
patient base. We believe the Biote Method will be a powerful
treatment tool for our clinics to help alleviate certain aspects of
obesity, which is a leading cause of chronic illness and back
pain.”
The Company has begun training IMAC medical
professionals in the Biote Method for launching the treatments at
select IMAC Regeneration Centers in September.
About
Biote
Biote is a woman-led company operating a high
growth, differentiated medical practice-building business within
the hormone optimization space. Similar to a franchise model, Biote
provides the necessary components to enable practitioners to
establish, build, and successfully operate a hormone optimization
center to treat patients appropriate for therapy. Biote trains
practitioners how to identify and treat early indicators of
hormone-related aging conditions.
About IMAC Holdings
IMAC Holdings owns and manages health and
wellness centers that deliver sports medicine, orthopedic care, and
restorative joint and tissue therapies for movement restricting
pain and neurodegenerative diseases. IMAC is comprised of
three business segments: outpatient medical centers, The Back
Space, and a clinical research division. With treatments to address
both young and aging populations, IMAC Holdings owns or
manages outpatient medical clinics that deliver regenerative
rehabilitation services as a minimally invasive approach to acute
and chronic musculoskeletal and neurological health problems.
IMAC’s The Back Company retail spinal health and wellness treatment
centers deliver chiropractic care within Walmart locations. IMAC’s
research division is currently conducting a Phase I clinical trial
evaluating a mesenchymal stem cell therapy candidate for
bradykinesia due to Parkinson’s disease. For more information
visit www.imacholdings.com.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Some of the
forward-looking statements can be identified by the use of
forward-looking words. Statements that are not historical in
nature, including the words “may,” “can,” “should,” “will,”
“estimate,” “plan,” “project,” “forecast,” “intend,” “expect,”
“hope,” “anticipate,” “believe,” “seek,” “target,” “continue,”
“could,” “might,” “ongoing,” “potential,” “predict,” “would” and
other similar expressions, are intended to identify forward-looking
statements. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual results or
developments to differ materially from those expressed or implied
by such forward-looking statements, including but not limited to:
the success of our dietary supplements to attain significant market
acceptance among clinics, practitioners and their patients; our
customers’ reliance on certain third parties to support the
manufacturing of bio-identical hormones for prescribers; our and
our customers’ sensitive to regulatory, economic, environmental and
competitive conditions in certain geographic regions; our ability
to increase the use by practitioners and clinics of the Biote
Method at the rate that we anticipate or at all; our ability to
grow our business; the significant competition we face in our
industry; our limited operating history; our ability to protect our
intellectual property; the unpredictability of the effects of the
COVID-19 pandemic; the heavy regulatory oversight in our industry;
changes in applicable laws or regulations; the inability to
profitably expand in existing markets and into new markets; the
possibility that we may be adversely impacted by other economic,
business and/or competitive factors and future exchange and
interest rates. The foregoing list of factors is not exhaustive.
You should carefully consider the foregoing factors and the other
risks and uncertainties described in the “Risk Factors” section of
Biote’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2022 and other documents filed
by Biote from time to time with the Securities and
Exchange Commission. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements,
and Biote assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or
otherwise. Biote does not give any assurance that it will
achieve its expectations.
Biote
Media ContactPress@biote.com
IMAC Holdings
Media Contactlfristoe@imacholdings.com
Biote (NASDAQ:BTMD)
過去 株価チャート
から 2 2025 まで 3 2025
Biote (NASDAQ:BTMD)
過去 株価チャート
から 3 2024 まで 3 2025